Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
A migraine is a moderate to severe headache described as a beating pain on one side of the head. It can be accompanied by other symptoms, including sensitivity to sounds and light, or feeling sick (nausea, vomiting).
Although the exact causes of migraines are still unknown, multiple studies have confirmed that release of calcitonin gene-related peptide (CGRP) is increased during acute migraine attacks.
The inhibition of CGRP and its receptor has proved effective in migraine pain relief, which suggests that it does contribute to the onset of a migraine.
Migraine attacks are usually different for different people and can vary also from attack to attack for the same person. Usually these 3 main types of migraine are distinguished:
The ‘aura’ of a migraine refers to sensory disturbances, that can include a wide range of neurological symptoms. It usually occurs between 5 to 60 minutes before the headache arises. Aura symptoms can be: changes in vision, numbness or tingling sensations, weakness and dizziness, or speech and hearing disturbances. Sufferers have reported memory changes, feelings of fear and confusion, and in some rare cases, partial paralysis or fainting.
Migraine attacks usually build up in stages:
Recognising the different stages of a migraine can be useful to help doctors give the right diagnosis and treatment.
Attacks may differ in length and frequency. Migraine attacks usually last from 4 to 72 hours and most people are symptom-free between attacks.
A migraine cure is not yet available, so treatment aims to relieve symptoms.
Among the medication typically used are:
There are currently five new treatments that target CGRP or its receptor. Four have been submitted to the Food and Drug Administration (FDA), and the fifth is in phase III clinical trials. These are: